71904-80-8

Basic information

• Product Name: 2-[[(TERT-BUTOXYCARBONYL)AMINO]METHYL]THIAZOLE-4-CARBOXYLIC ACID
• Synonyms: 2-[[(TERT-BUTOXYCARBONYL)AMINO]METHYL]THIAZOLE-4-CARBOXYLIC ACID;2-(Aminomethyl)-1,3-thiazole-4-carboxylic acid, 2-BOC protected;2-{[(tert-Butoxycarbonyl)amino]methyl}-1,3-thiazole-4-carboxylic acid
• CAS NO: 71904-80-8
• Molecular Formula: C₁₀H₁₄N₂O₄S
• Molecular Weight: 258.29
• Mol File: 71904-80-8.mol
• Article Data: 24

Chemical Properties

• Melting Point: 178-179℃
• Boiling Point: 438.216 °C at 760 mmHg
• Flash Point: 218.826 °C
• Appearance: /
• Density: 1.319 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.557
• PKA: 11.27±0.46(Predicted)
• CAS DataBase Reference: 2-[[(TERT-BUTOXYCARBONYL)AMINO]METHYL]THIAZOLE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[[(TERT-BUTOXYCARBONYL)AMINO]METHYL]THIAZOLE-4-CARBOXYLIC ACID(71904-80-8)
• EPA Substance Registry System: 2-[[(TERT-BUTOXYCARBONYL)AMINO]METHYL]THIAZOLE-4-CARBOXYLIC ACID(71904-80-8)

Safety Data

• Hazardous Substances Data: 71904-80-8(Hazardous Substances Data)

Usage

General Description

2-[(tert-butoxycarbonyl)amino]methyl]thiazole-4-carboxylic acid is a chemical compound with a molecular formula C13H19N3O4S and a molecular weight of 313.37 g/mol. It is a thiazole derivative that contains a tert-butoxycarbonyl (Boc) protecting group, a common type of chemical modification used to protect amines in organic synthesis. 2-[[(TERT-BUTOXYCARBONYL)AMINO]METHYL]THIAZOLE-4-CARBOXYLIC ACID is often used in the synthesis of pharmaceuticals and as a building block for more complex molecules. The thiazole-4-carboxylic acid moiety also confers potential biological activity, as thiazole derivatives have been studied for their antimicrobial, antifungal, and antiproliferative properties. Overall, 2-[(tert-butoxycarbonyl)amino]methyl]thiazole-4-carboxylic acid is a versatile compound with potential applications in medicinal chemistry and drug development.

InChI:InChI=1/C10H14N2O4S/c1-10(2,3)16-9(15)11-4-7-12-6(5-17-7)8(13)14/h5H,4H2,1-3H3,(H,11,15)(H,13,14)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 25438-22-6 Gly-Thz 
• 297165-32-3 methyl 2-(tert-butoxycarbonylaminomethyl)thiazole-4-carboxylate 
• 85363-04-8 tert-butyl cyanomethylcarbamate 
• 88219-00-5 ethyl 2-(benzamidomethyl)thiazole-4-carboxylate 
• 95104-84-0 Boc-Gly-OCOOEt 
• 89226-13-1 2-(N-t-butoxycarbonylamino)thioacetamide 
• 4530-20-5 BOC-glycine 
• 95716-02-2 H-(gly)Thz-OMe*HBr 
• 35150-09-5 N-(tert-butoxycarbonyl)glycine 
• 96929-05-4 ethyl 2-[N-(tert-butoxycarbonyl)aminomethyl]thiazole-4-carboxylate 
• 63628-60-4 2-(aminomethyl)thiazole-4-carboxylic acid hydrochloride 
• 1113-59-3 bromopyruvic acid 

Downstream Products

• 63628-60-4 2-(aminomethyl)thiazole-4-carboxylic acid hydrochloride 
• 1415580-99-2 C₃₈H₃₉N₇O₄S₂ 
• 1415580-98-1 (9S,12S)-9-isopropyl-12-((E)-4-(tritylthio)but-1-en-1-yl)-11-oxa-18-thia-3,4,5,8,15,20,21-heptaazatricyclo[15.2.1.1^2,5]henicosa-1⁽¹⁹⁾,2⁽²¹⁾,3,17⁽²⁰⁾-tetraene-7,10,14-trione 
• 1415580-95-8 (S,E)-2-(trimethylsilyl)ethyl 3-(((S)-2-(2-(5-(2-(((tert-butoxycarbonyl)amino)methyl)thiazol-4-yl)-2H-tetrazol-2-yl)acetamido)-3-methylbutanoyl)oxy)-7-(tritylthio)hept-4-enoate 
• 1092363-40-0 (4R)-methyl 2-(2-((8S)-1-(9H-fluoren-9-yl)-5-isopropyl-3,6,10-trioxo-8-((E)-4-(tritylthio)-but-1-enyl)-2,7-dioxa-4,11-diazadodecan-12-yl)thiazol-4-yl)-4-methyl-4,5-dihydrothiazole-4-carboxylate 
• 1092363-37-5 (R)-methyl 2-(2-(((3S,4E)-3-hydroxy-7-(tritylthio)hept-4-enamido)methyl)thiazol-4-yl)-4-methyl-4,5-dihydrothiazole-4-carboxylate 
• 1338230-01-5 C₂₈H₃₄N₄O₅S₃ 
• 1191242-43-9 C₄₀H₄₄N₄O₅S₃ 
• 1092363-38-6 C₅₅H₅₄N₄O₇S₃ 
• 1315334-38-3 (S,E)-2-(trimethylsilyl)ethyl 3-((S)-2-(2-(2-((tert-butoxycarbonylamino)methyl)thiazole-4-carboxamido)-2-methylpropanamido)-3-methylbutanoyloxy)-7-(tritylthio)hept-4-enoate 
• 1315334-35-0 (5R,12S)-5-methyl-12-((E)-4-(tritylthio)but-1-en-1-yl)-11-oxa-3,18-dithia-7,15,20,21-tetraazatricyclo[15.2.1.1(2,5)]henicosa-1⁽¹⁹⁾,2⁽²¹⁾,17⁽²⁰⁾-triene-6,10,14-trione 
• 1315334-33-8 (S,E)-2-(trimethylsilyl)ethyl 3-(3-((R)-2-(2-((tert-butoxycarbonylamino)methyl)thiazol-4-yl)-4-methyl-4,5-dihydrothiazole-4-carboxamido)propanoyloxy)-7-(tritylthio)hept-4-enoate 
• 1315334-34-9 (5R,11S)-5-methyl-11-((E)-4-(tritylthio)but-1-en-1-yl)-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1(2,5)]icosa-1⁽¹⁸⁾,2⁽²⁰⁾,16⁽¹⁹⁾-triene-6,9,13-trione 
• 1315334-32-7 (S,E)-2-(trimethylsilyl)ethyl 3-(2-((R)-2-(2-((tert-butoxycarbonylamino)methyl)thiazol-4-yl)-4-methyl-4,5-dihydrothiazole-4-carboxamido)acetoxy)-7-(tritylthio)hept-4-enoate 

Relevant articles and documents

First total synthesis of aerucyclamide B

The first total synthesis of the antimalarial aerucyclamide B has been achieved in 9% overall yield. Two thiazoles and a dipeptide were used to prepare two open precursors of cyclo-Gly-l-allo-Thr-l-Ile-Thz-d-allo-Ile-Thz. Cyclodehydration with Deoxo-Fluor of the β-hydroxyamide present in the macrocycle, rendered aerucyclamide B (67%) and an unexpected fluorous derivative (28%).

Analog of dolastatin 3. Synthesis, 1H NMR studies and spatial conformation

-

Synthesis of a Microcystis aeruginosa predicted metabolite with antimalarial activity

The synthesis of a Microcystis aeruginosa predicted metabolite analog of aerucyclamide B was performed. This hexacyclopeptide was obtained from three heterocyclic building blocks by a convergent macrocycle-assembly methodology. The compound exhibited good in vitro antiplasmodial activity (IC50: 0.18 μM, K1, cholorquine resistant strain).

Total Synthesis of the Post-translationally Modified Polyazole Peptide Antibiotic Goadsporin

The structurally unique polyazole antibiotic goadsporin contains six heteroaromatic oxazole and thiazole rings integrated into a linear array of amino acids that also contains two dehydroalanine residues. An efficient total synthesis of goadsporin is repo

Discovery of Novel Class i Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities

A successful structure-based design of novel cyclic depsipeptides that selectively target class I HDAC isoforms is described. Compound 11 has an IC50 of 2.78 nM for binding to the HDAC1 protein, and the prodrugs 12 and 13 also exhibit promising antiproliferative activities in the nanomolar range against various cancer cell lines. Compounds 12 and 13 show more than 20-fold selectivity toward human cancer cells over human normal cells in comparison with romidepsin (FK228), demonstrating low probability of toxic side effects. In addition, compound 13 exhibits excellent in vivo anticancer activities in a human prostate carcinoma (Du145) xenograft model with no observed toxicity. Thus, prodrug 13 has therapeutic potential as a new class of anticancer agent for further clinical translation.